[PDF][PDF] Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer
J Nemunaitis, RO Dillman… - Journal of Clinical …, 2006 - researchgate.net
J Nemunaitis, RO Dillman, PO Schwarzenberger, N Senzer, C Cunningham, J Cutler…
Journal of Clinical Oncology, 2006•researchgate.netPhase II Study of Belagenpumatucel-L, a Transforming Growth Factor Beta-2 Antisense
Gene-Modified Allogeneic Tumor Cell Vaccine Page 1 Phase II Study of Belagenpumatucel-L,
a Transforming Growth Factor Beta-2 Antisense Gene-Modified Allogeneic Tumor Cell
Vaccine in Non–Small-Cell Lung Cancer John Nemunaitis, Robert O. Dillman, Paul O.
Schwarzenberger, Neil Senzer, Casey Cunningham, Jodi Cutler, Alex Tong, Padmasini
Kumar, Beena Pappen, Cody Hamilton, Edward DeVol, Phillip B. Maples, Lily Liu, Terry …
Gene-Modified Allogeneic Tumor Cell Vaccine Page 1 Phase II Study of Belagenpumatucel-L,
a Transforming Growth Factor Beta-2 Antisense Gene-Modified Allogeneic Tumor Cell
Vaccine in Non–Small-Cell Lung Cancer John Nemunaitis, Robert O. Dillman, Paul O.
Schwarzenberger, Neil Senzer, Casey Cunningham, Jodi Cutler, Alex Tong, Padmasini
Kumar, Beena Pappen, Cody Hamilton, Edward DeVol, Phillip B. Maples, Lily Liu, Terry …
Purpose
Belagenpumatucel-L is a nonviral gene-based allogeneic tumor cell vaccine that demonstrates enhancement of tumor antigen recognition as a result of transforming growth factor beta-2 inhibition.
researchgate.net